UY35356A - Nueva sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen - Google Patents

Nueva sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen

Info

Publication number
UY35356A
UY35356A UY0001035356A UY35356A UY35356A UY 35356 A UY35356 A UY 35356A UY 0001035356 A UY0001035356 A UY 0001035356A UY 35356 A UY35356 A UY 35356A UY 35356 A UY35356 A UY 35356A
Authority
UY
Uruguay
Prior art keywords
abexinostat
salt
new
pharmaceutical compositions
compositions containing
Prior art date
Application number
UY0001035356A
Other languages
English (en)
Inventor
Anne Pimont-Garro
Philippe Letellier
Original Assignee
Servier Lab
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35356(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Pharmacyclics Inc filed Critical Servier Lab
Publication of UY35356A publication Critical patent/UY35356A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Tosilato de abexinostat de fórmula (II): y su forma cristalina I caracterizada por su diagrama de difracción X de polvo, su espectro Raman, y su esp ectro RMN en estado sólido 13C CP/MAS. Medicamentos
UY0001035356A 2013-03-04 2014-02-27 Nueva sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen UY35356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
UY35356A true UY35356A (es) 2014-09-30

Family

ID=48521256

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035356A UY35356A (es) 2013-03-04 2014-02-27 Nueva sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen

Country Status (39)

Country Link
US (3) US9115108B2 (es)
EP (2) EP3252044A1 (es)
JP (2) JP6449177B2 (es)
CN (2) CN105263917B (es)
AR (1) AR094935A1 (es)
AU (2) AU2014224456B2 (es)
BR (1) BR112015021443A2 (es)
CA (1) CA2903369C (es)
CL (1) CL2015002488A1 (es)
CR (1) CR20150456A (es)
CY (1) CY1119147T1 (es)
DK (1) DK2964622T3 (es)
DO (1) DOP2015000215A (es)
EA (2) EA039113B1 (es)
ES (1) ES2632471T3 (es)
FR (1) FR3002733B1 (es)
GE (1) GEP201706760B (es)
HK (1) HK1220965A1 (es)
HR (1) HRP20171041T1 (es)
HU (1) HUE035299T2 (es)
IL (1) IL241038B (es)
JO (1) JO3402B1 (es)
LT (1) LT2964622T (es)
MA (1) MA38423B1 (es)
ME (1) ME02814B (es)
MX (1) MX355436B (es)
MY (1) MY192027A (es)
NI (1) NI201500122A (es)
PE (1) PE20151591A1 (es)
PL (1) PL2964622T3 (es)
PT (1) PT2964622T (es)
RS (1) RS56224B1 (es)
SG (1) SG11201506952YA (es)
SI (1) SI2964622T1 (es)
TN (1) TN2015000367A1 (es)
TW (1) TWI506023B (es)
UA (1) UA118550C2 (es)
UY (1) UY35356A (es)
WO (1) WO2014135776A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ789041A (en) 2010-06-03 2023-09-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN105008344B (zh) 2012-11-02 2017-07-25 辉瑞公司 布鲁顿氏酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG10201901916WA (en) * 2014-09-03 2019-04-29 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
EP4351734A1 (en) 2021-06-10 2024-04-17 Teva Pharmaceuticals International GmbH Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
BRPI0409227C1 (pt) * 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AU2010299483B2 (en) * 2009-09-24 2014-08-28 Sun Pharmaceutical Industries Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
LT2964622T (lt) 2017-08-10
HUE035299T2 (en) 2018-05-02
US20170313671A1 (en) 2017-11-02
AU2018202881B2 (en) 2020-02-27
EA201891023A1 (ru) 2019-03-29
EP2964622B1 (fr) 2017-04-19
US10150748B2 (en) 2018-12-11
PT2964622T (pt) 2017-07-13
US20140249215A1 (en) 2014-09-04
FR3002733B1 (fr) 2015-08-14
HRP20171041T1 (hr) 2017-10-06
HK1220965A1 (zh) 2017-05-19
MX2015011566A (es) 2016-06-24
RS56224B1 (sr) 2017-11-30
ES2632471T3 (es) 2017-09-13
IL241038B (en) 2019-09-26
NZ712380A (en) 2020-10-30
PL2964622T3 (pl) 2017-10-31
JO3402B1 (ar) 2019-10-20
BR112015021443A2 (pt) 2017-07-18
AU2018202881A1 (en) 2018-05-17
MX355436B (es) 2018-04-18
AU2014224456A1 (en) 2015-10-08
CR20150456A (es) 2015-10-21
PE20151591A1 (es) 2015-11-06
MY192027A (en) 2022-07-23
CA2903369C (en) 2021-06-08
GEP201706760B (en) 2017-10-25
EP3252044A1 (fr) 2017-12-06
AR094935A1 (es) 2015-09-09
CL2015002488A1 (es) 2016-03-11
WO2014135776A1 (fr) 2014-09-12
JP2016510735A (ja) 2016-04-11
FR3002733A1 (fr) 2014-09-05
JP2019069955A (ja) 2019-05-09
EA201591530A1 (ru) 2016-01-29
SI2964622T1 (sl) 2017-10-30
EP2964622A1 (fr) 2016-01-13
CN109734690A (zh) 2019-05-10
CA2903369A1 (en) 2014-09-12
TWI506023B (zh) 2015-11-01
JP6449177B2 (ja) 2019-01-09
ME02814B (me) 2018-01-20
MA38423B1 (fr) 2017-10-31
CN109734690B (zh) 2023-08-11
CN105263917A (zh) 2016-01-20
EA039113B1 (ru) 2021-12-06
EA030689B1 (ru) 2018-09-28
UA118550C2 (uk) 2019-02-11
CY1119147T1 (el) 2018-02-14
AU2014224456A8 (en) 2015-10-22
NI201500122A (es) 2018-10-18
MA38423A1 (fr) 2017-02-28
DOP2015000215A (es) 2015-09-30
TN2015000367A1 (fr) 2017-01-03
TW201434822A (zh) 2014-09-16
US9115108B2 (en) 2015-08-25
AU2014224456B2 (en) 2018-01-25
DK2964622T3 (en) 2017-07-31
US20150315167A1 (en) 2015-11-05
JP6720280B2 (ja) 2020-07-08
SG11201506952YA (en) 2015-10-29
CN105263917B (zh) 2018-11-20
IL241038A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
UY35356A (es) Nueva sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20160033A (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015013042A (es) Compuestos organicos.
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
UA117020C2 (uk) Нові сполуки індолу і піролу, спосіб їх одержання і фармацевтичні композиції, що їх містять
CO2018003473A2 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
PH12015502632A1 (en) Cxcr7 receptor modulators
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201600394A1 (ru) Трициклические соединения пиперидина
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν
CR20120655A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201400444A1 (ru) Производные 2-оксопиперидинила
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211110